Catalyst Pharmaceuticals CEO Richard J. Daly to Present at 43rd Annual J.P. Morgan Healthcare Conference
Catalyst Pharmaceuticals CEO Richard J. Daly to Present at 43rd Annual J.P. Morgan Healthcare Conference
Richard J. Daly, CEO of Catalyst Pharmaceuticals, will present at the J.P. Morgan Healthcare Conference on January 16, 2025.
Quiver AI Summary
Catalyst Pharmaceuticals, Inc. announced that Richard J. Daly, the company's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 16, 2025, at 10:30 am PST. The presentation will be available via a webcast on Catalyst's website, and a replay will be accessible for 30 days after the event. Catalyst, which focuses on developing and commercializing treatments for rare diseases, has been recognized as one of North America's fastest-growing companies by Deloitte. The company is headquartered in Coral Gables, Florida, and is committed to improving patient care through innovative therapies and comprehensive support services.
Potential Positives
- Richard J. Daly, President and CEO of Catalyst, will present at the prestigious 43rd Annual J.P. Morgan Healthcare Conference, highlighting the company's visibility and commitment to investor engagement.
- Catalyst Pharmaceuticals is recognized for its rapid growth, being listed among North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List, indicating strong performance and market potential.
- The company maintains a focus on innovative therapies for rare diseases, showcasing its dedication to improving patient care and addressing significant unmet medical needs in the market.
Potential Negatives
- The forward-looking statements section acknowledges known and unknown risks and uncertainties that could affect the company's actual results negatively, which may indicate potential volatility in their future performance.
- The mention of various factors that could adversely affect the company hints at underlying issues that may not be clearly disclosed or understood by investors.
- The absence of new product announcements or specific strategic initiatives in the press release may signal stagnation in the company's growth and innovation efforts.
FAQ
What will Richard J. Daly present at the J.P. Morgan Healthcare Conference?
Richard J. Daly, President and CEO of Catalyst, will present on January 16, 2025, at the conference.
How can I access the webcast of the presentation?
The webcast will be available under the Investors section on Catalyst Pharmaceuticals' website.
What is Catalyst Pharmaceuticals focused on?
Catalyst Pharmaceuticals focuses on developing and commercializing novel medicines for rare and difficult-to-treat diseases.
When was Catalyst recognized as a Fastest-Growing Company?
Catalyst was recognized as one of North America's Fastest-Growing Companies in the 2024 Deloitte Technology Fast 500 List.
Where is Catalyst Pharmaceuticals headquartered?
Catalyst Pharmaceuticals is headquartered in Coral Gables, Florida.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CPRX Insider Trading Activity
$CPRX insiders have traded $CPRX stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here's a breakdown of recent trading of $CPRX stock by insiders over the last 6 months:
- STEVE MILLER (Chief Op. & Scientific Officer) has traded it 4 times. They made 0 purchases and 4 sales, selling 200,000 shares.
- GARY INGENITO (Chief Med. & Reg. Officer) has traded it 4 times. They made 0 purchases and 4 sales, selling 150,000 shares.
- MOLLY HARPER sold 17,500 shares.
- BRIAN ELSBERND (Chief Compliance/Legal Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 13,256 shares.
- PATRICK J MCENANY has traded it 7 times. They made 0 purchases and 7 sales, selling 800,000 shares.
- DAVID S TIERNEY sold 15,000 shares.
- CARMEN JEFFREY DEL (Chief Commercial Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 36,058 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CPRX Hedge Fund Activity
We have seen 160 institutional investors add shares of $CPRX stock to their portfolio, and 145 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) removed 2,897,671 shares (-31.7%) from their portfolio in Q3 2024
- JANUS HENDERSON GROUP PLC removed 1,815,450 shares (-83.4%) from their portfolio in Q3 2024
- MORGAN STANLEY added 810,595 shares (+80.0%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. removed 618,296 shares (-100.0%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 557,683 shares (-95.7%) from their portfolio in Q3 2024
- QUBE RESEARCH & TECHNOLOGIES LTD added 538,506 shares (+418.3%) to their portfolio in Q3 2024
- OPALEYE MANAGEMENT INC. removed 527,500 shares (-82.4%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA.
43rd Annual J.P. Morgan Healthcare Conference Presentation Details
Date : | Thursday, January 16, 2025 | |
Time: | 10:30 am PST | |
Webcast: | Link |
The webcast will be available under the Investors section on the Company's website at
,
and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, FL., was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List.
For more information, please visit Catalyst's website at
.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
